Key Developments: Catalyst Pharmaceutical Partners Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.37USD
25 Jul 2014
Price Change (% chg)

$0.02 (+0.85%)
Prev Close
$2.35
Open
$2.35
Day's High
$2.40
Day's Low
$2.34
Volume
11,068
Avg. Vol
82,765
52-wk High
$3.63
52-wk Low
$1.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceutical Partners Inc announces closing of public offering
Tuesday, 8 Apr 2014 10:30am EDT 

Catalyst Pharmaceutical Partners Inc:Closes public offering of shares of common stock.Company sold 13,023,750 shares of common stock in offering, including 1,698,750 shares that were issued upon exercise by underwriters of their overallotment option.Offering price was $2.21 per share, and net proceeds from sale of shares is expected to be $26.8 mln.Piper Jaffray & Co. acted as sole book-running manager for offering, Roth Capital Partners acted as co-lead manager, and H.C. Wainwright & Co., LLC acted as co-manager with respect to offering.  Full Article

Catalyst Pharmaceutical Partners prices public offering of common stock
Thursday, 3 Apr 2014 09:00am EDT 

Catalyst Pharmaceutical Partners Inc:Prices underwritten public offering of 11,325,000 shares of common stock at $2.21 per share.Grantes underwriters a 30-day option to purchase up to an additional 1,698,750 shares to cover over-allotments.Expects net proceeds to be about $23.3 mln.To use net proceeds for development of Firdapse or LEMS for pre-commercialization activities relating to Firdapse, for development of CPP-115 and for general corporate purposes.Expected to close on April 8.Piper Jaffray & Co is sole book-running manager.Roth Capital Partners co-lead manager.H.C. Wainwright & Co LLC is co-manager.  Full Article

Catalyst Pharmaceutical Partners Inc announces commencement of public offering of common stock
Wednesday, 2 Apr 2014 04:04pm EDT 

Catalyst Pharmaceutical Partners Inc:Intends to offer shares of its common stock in a public offering.Plans to use net proceeds from offering for continuing development of Firdapse for treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS.For pre-commercialization activities relating to Firdapse.Forcontinuing development of CPP-115and for general corporate purposes.Piper Jaffray & Co. is acting as the sole book-running manager.  Full Article

Catalyst Pharmaceutical Partners Inc announces recommendation of data monitoring committee to continue pivotal phase three clinical trial for firdapse
Tuesday, 25 Mar 2014 08:03am EDT 

Catalyst Pharmaceutical Partners Inc:At a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing its ongoing pivotal Phase three clinical trial evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).Recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.The international, multicenter Firdapse phase three clinical trial is designed as a randomized, double-blind, placebo-controlled, discontinuation trial enrolling 36 patients diagnosed with LEMS.The trial is being conducted at 22 centers in the United States, Canada, South America and Europe.  Full Article

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Catalyst Pharmaceutical Partners Inc
Tuesday, 12 Nov 2013 07:15pm EST 

Glancy Binkow & Goldberg LLP announced that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of a class (the Class) comprising all purchasers of the securities of Catalyst Pharmaceutical Partners Inc between October 31, 2012 and October 18, 2013, inclusive (the Class Period). The Complaint alleges that the defendants failed to disclose that one of Catalyst`s competitors - a private pharmaceutical company - has been manufacturing a drug biologically equivalent to Firdapse, and providing it to patients with LEMS, free of charge, through a compassionate use program. On October 18, 2013, an article published by The Street stated that Catalyst`s Firdapse was the same drug that its competitor has been manufacturing and providing in the U.S. for at least two decades.  Full Article

Investor Files Federal Securities Fraud Class Action Complaint Against Catalyst Pharmaceutical Partners Inc
Tuesday, 12 Nov 2013 06:25pm EST 

Shareholder rights law firm Robbins Arroyo LLP announced that an investor of Catalyst Pharmaceutical Partners Inc has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of Florida. The complaint alleges that the Company and certain of its officers violated the Securities and Exchange Act of 1934 between October 31, 2012 and October 18, 2013 (the Class Period). Catalyst is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The Company's lead drug candidate, Firdapse, is a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS); a rare, neuromuscular disease which causes progressive muscle weakness. According to the complaint, the Company made false and misleading failed statements and/or failed to disclose material adverse facts about the Company's business prospects. Specifically, the complaint alleges that Catalyst failed to disclose to investors that its competitor, Jacobus Pharmaceuticals, has for twenty years provided LEMS patients in the United States an equivalent to Firdapse, free of charge through an FDA approved compassionate use program. On October 18, 2013, The Street issued an article revealing Jacobus' free alterative to Catalyst's Firdapse. On this news, Catalyst shares fell to $1.52 or 25% on October 21, 2013.  Full Article

Rigrodsky & Long, P.A. Announces Class Action Lawsuit Filed Against Catalyst Pharmaceutical Partners, Inc
Monday, 28 Oct 2013 04:58pm EDT 

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announced that a complaint has been filed in the United States District Court for the Southern District of Florida on behalf of all persons or entities that purchased the common stock of Catalyst Pharmaceutical Partners, Inc. (Catalyst or the Company) between October 31, 2012 and October 18, 2013, inclusive (the Class Period), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the Complaint).  Full Article

Catalyst Pharmaceutical Partners Inc Closes Previously Announced $15.1 Million Registered Direct Offering
Tuesday, 10 Sep 2013 11:52am EDT 

Catalyst Pharmaceutical Partners Inc announced that it has closed its previously announced offering of 8.8 million shares of its common stock in a registered direct public offering. The offering price was $1.72 per share, resulting in gross proceeds of approximately $15.1 million. Roth Capital Partners acted as the exclusive placement agent for the offering and Aegis Capital Corp., Maxim Group LLC and H.C. Wainwright & Co. acted as financial advisers with respect to the offering.  Full Article

Catalyst Pharmaceutical Partners Inc Announces Offering Of Shares - Form 8-K
Thursday, 5 Sep 2013 09:16am EDT 

Catalyst Pharmaceutical Partners Inc reported in its Form 8-K that it has entered into Subscription Agreements (collectively, the Subscription Agreement) with investors who agreed to purchase an aggregate of 8,800,000 shares (the Shares) of the Company’s common stock, par value $0.001 per share for a purchase price of $1.72 per Share, or an aggregate of $15.1 million in gross proceeds. Roth Capital Partners, LLC (“Roth”) acted as Placement Agent for the offering of the Shares (the Offering). Further, Aegis Capital Corporation, Maxim Group LLC and H.C. Wainright & Co. acted as financial advisors in connection with the offering. The closing of the Offering is expected to take place on September 10, 2013, subject to the satisfaction of customary closing conditions.  Full Article

Catalyst Pharmaceutical Partners Inc Receives Breakthrough Therapy Designation From FDA For Firdapse For Treatment Of LEMS
Tuesday, 27 Aug 2013 08:03am EDT 

Catalyst Pharmaceutical Partners Inc announced that investigational product Firdapse (amifampridine phosphate) has received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse is Catalyst's investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.  Full Article

Search Stocks